RE:RE:RE:Trevor MacDougall and Paul Sanders - Lumeda Co-foundersHempdoc wrote:
Eoganacht wrote: It looks like one big happy collaboration to me. Roswell Park is doing the research using their patented optical surface applicator (OSA), Lumeda is fine tuning the OSA for the IO-PDT of NSCLC and Theralase is providing the patented photosensitizer TLD-1433 to replace photofrin, which was being considered previously. And this whole project is for IO-PDT in cases where lung tumours are being surgically removed. NSCLC PDT using fiberoptic bronchoscopy is still to come.
Boy, does TLT like to lay low...may be waiting for in vivo/animal confirmation of efficacy before we get news? But you couldn't have dreamed a better collaboration amongst top experts in their respective fields. And lumeda's experience in photonics & larger-scale manufacturing with previously "successful" commercialization would make an ideal partner for TLT. We probably should have dumped our cold laser division a while ago & used all of our efforts/monies/resources on making real "advances", & more importantly, real "profits" in medicine. That certainly won't come from cold laser...how many more years will it take TLT to figure that out. Not a lot of business sense happening here imo. If it weren't for Sherri, where would we honestly be...?
I dunno Doc,
I still think TLT could do something with that CLT cancer pre-treatment tech. That could be rolled out fairly quickly and worth multiple $Bs. But you are correct about the when? This fricken company takes forever to do anything!